{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:49Z","timestamp":1787841529765,"version":"build-2784847793"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01878-9","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:31:59Z","timestamp":1781587919000},"page":"1059-1069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-6118","authenticated-orcid":false,"given":"Bogdan-Valentin","family":"Popescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Blaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Fl\u00e8che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Guermazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Stancu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eete","family":"Mery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Limacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erion","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Leheurteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1878_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13053-022-00242-0","volume":"20","author":"O Caramelo","year":"2022","unstructured":"Caramelo O, Silva C, Caramelo F, et al. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis. Hered Cancer Clin Pract. 2022;20:34. https:\/\/doi.org\/10.1186\/s13053-022-00242-0.","journal-title":"Hered Cancer Clin Pract"},{"key":"1878_CR2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/modpathol.2010.200","volume":"24","author":"S Badve","year":"2011","unstructured":"Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157\u201367. https:\/\/doi.org\/10.1038\/modpathol.2010.200.","journal-title":"Mod Pathol"},{"key":"1878_CR3","doi-asserted-by":"publisher","first-page":"836417","DOI":"10.3389\/fmolb.2022.836417","volume":"9","author":"NM Almansour","year":"2022","unstructured":"Almansour NM. Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence. Front Mol Biosci. 2022;9:836417. https:\/\/doi.org\/10.3389\/fmolb.2022.836417.","journal-title":"Front Mol Biosci"},{"key":"1878_CR4","doi-asserted-by":"publisher","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2023;S0923753423051049. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"1878_CR5","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194\u2013220. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","journal-title":"Ann Oncol"},{"key":"1878_CR6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090\u2013100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X.","journal-title":"Lancet"},{"key":"1878_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","volume":"33","author":"S Loibl","year":"2022","unstructured":"Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33:1149\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1940.","journal-title":"Ann Oncol"},{"key":"1878_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382:810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1910549.","journal-title":"N Engl J Med"},{"key":"1878_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","volume":"145","author":"P Sharma","year":"2014","unstructured":"Sharma P, Klemp JR, Kimler BF, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145:707\u201314. https:\/\/doi.org\/10.1007\/s10549-014-2980-0.","journal-title":"Breast Cancer Res Treat"},{"key":"1878_CR10","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41698-024-00559-0","volume":"8","author":"WK Park","year":"2024","unstructured":"Park WK, Chung SY, Jung YJ, et al. Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1\/2 mutations. Npj Precis Oncol. 2024;8:96. https:\/\/doi.org\/10.1038\/s41698-024-00559-0.","journal-title":"Npj Precis Oncol"},{"key":"1878_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34:33\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.004.","journal-title":"Ann Oncol"},{"key":"1878_CR12","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer. N Engl J Med. 2021;384:2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med"},{"key":"1878_CR13","doi-asserted-by":"publisher","first-page":"100664","DOI":"10.1016\/j.esmorw.2025.100664","volume":"11","author":"J McKeon","year":"2026","unstructured":"McKeon J, Daniels E, Halstead A, et al. UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer. ESMO Real World Data Digit Oncol. 2026;11:100664. https:\/\/doi.org\/10.1016\/j.esmorw.2025.100664.","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"1878_CR14","doi-asserted-by":"publisher","first-page":"8854","DOI":"10.3390\/jcm14248854","volume":"14","author":"P Fedele","year":"2025","unstructured":"Fedele P, Rizzo A, Landriscina M, et al. BRCA1 and 2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter Analysis. J Clin Med. 2025;14:8854. https:\/\/doi.org\/10.3390\/jcm14248854.","journal-title":"J Clin Med"},{"key":"1878_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/1477-7819-12-95","volume":"12","author":"K Wu","year":"2014","unstructured":"Wu K, Yang Q, Liu Y, et al. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol. 2014;12:95. https:\/\/doi.org\/10.1186\/1477-7819-12-95.","journal-title":"World J Surg Oncol"},{"key":"1878_CR16","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.humpath.2014.10.020","volume":"46","author":"VMT Van Verschuer","year":"2015","unstructured":"Van Verschuer VMT, Hooning MJ, Van Baare-Georgieva RD, et al. Tumor-associated inflammation as a potential prognostic tool in BRCA1\/2-associated breast cancer. Hum Pathol. 2015;46:182\u201390. https:\/\/doi.org\/10.1016\/j.humpath.2014.10.020.","journal-title":"Hum Pathol"},{"key":"1878_CR17","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587\u201398. https:\/\/doi.org\/10.18632\/oncotarget.7277.","journal-title":"Oncotarget"},{"key":"1878_CR18","doi-asserted-by":"publisher","first-page":"17501","DOI":"10.18632\/oncotarget.24770","volume":"9","author":"V Wieser","year":"2018","unstructured":"Wieser V, Gaugg I, Fleischer M, et al. BRCA1\/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget. 2018;9:17501\u201311. https:\/\/doi.org\/10.18632\/oncotarget.24770.","journal-title":"Oncotarget"},{"key":"1878_CR19","doi-asserted-by":"publisher","first-page":"eaal4922","DOI":"10.1126\/scitranslmed.aal4922","volume":"9","author":"E Nolan","year":"2017","unstructured":"Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer. Sci Transl Med. 2017;9:eaal4922. https:\/\/doi.org\/10.1126\/scitranslmed.aal4922.","journal-title":"Sci Transl Med"},{"key":"1878_CR20","doi-asserted-by":"publisher","unstructured":"Audeh M, Dadmanesh F, Yearley J. Abstract P4-04-01: PDL-1 expression in primary breast cancers with germline mutations in BRCA 1 and 2. Cancer Res. 2016;76. https:\/\/doi.org\/10.1158\/1538-7445.SABCS15-P4-04-01. :P4-04-01-P4-04-01.","DOI":"10.1158\/1538-7445.SABCS15-P4-04-01"},{"key":"1878_CR21","doi-asserted-by":"publisher","first-page":"e17057","DOI":"10.1200\/JCO.2016.34.15_suppl.e17057","volume":"34","author":"JC Sachdev","year":"2016","unstructured":"Sachdev JC, Arguello D, Abbott BL, Reddy SK. PD-1, PD-L1 in BRCA1\/2-mutated and non-mutated epithelial ovarian carcinomas (EOCs). J Clin Oncol. 2016;34:e17057\u201317057. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.e17057.","journal-title":"J Clin Oncol"},{"key":"1878_CR22","doi-asserted-by":"publisher","first-page":"e1509820","DOI":"10.1080\/2162402X.2018.1509820","volume":"7","author":"M Sobral-Leite","year":"2018","unstructured":"Sobral-Leite M, Van De Vijver K, Michaut M, et al. Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1 -like status, tumor-infiltrating immune cells and survival. OncoImmunology. 2018;7:e1509820. https:\/\/doi.org\/10.1080\/2162402X.2018.1509820.","journal-title":"OncoImmunology"},{"key":"1878_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.02.027","volume":"450","author":"C Solinas","year":"2019","unstructured":"Solinas C, Marcoux D, Garaud S, et al. BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Lett. 2019;450:88\u201397. https:\/\/doi.org\/10.1016\/j.canlet.2019.02.027.","journal-title":"Cancer Lett"},{"key":"1878_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12885-019-5595-3","volume":"19","author":"L Lu","year":"2019","unstructured":"Lu L, Huang H, Zhou J, et al. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer. BMC Cancer. 2019;19:387. https:\/\/doi.org\/10.1186\/s12885-019-5595-3.","journal-title":"BMC Cancer"},{"key":"1878_CR25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1038\/s43018-020-00139-8","volume":"1","author":"RM Samstein","year":"2020","unstructured":"Samstein RM, Krishna C, Ma X, et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 2020;1:1188\u2013203. https:\/\/doi.org\/10.1038\/s43018-020-00139-8.","journal-title":"Nat Cancer"},{"key":"1878_CR26","doi-asserted-by":"publisher","first-page":"104473","DOI":"10.1016\/j.breast.2025.104473","volume":"83","author":"MDO Andrade","year":"2025","unstructured":"Andrade MDO, Gutierres IG, Tavares MC, et al. Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real\/GBECAM 0123 study. Breast. 2025;83:104473. https:\/\/doi.org\/10.1016\/j.breast.2025.104473.","journal-title":"Breast"},{"key":"1878_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s10549-026-07930-8","volume":"216","author":"M Sterpi","year":"2026","unstructured":"Sterpi M, Dreyfus N, Lo Y, et al. Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study. Breast Cancer Res Treat. 2026;216:18. https:\/\/doi.org\/10.1007\/s10549-026-07930-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1878_CR28","doi-asserted-by":"publisher","first-page":"2275846","DOI":"10.1080\/2162402X.2023.2275846","volume":"12","author":"M Marhold","year":"2023","unstructured":"Marhold M, Udovica S, Halstead A, et al. Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer. OncoImmunology. 2023;12:2275846. https:\/\/doi.org\/10.1080\/2162402X.2023.2275846.","journal-title":"OncoImmunology"},{"key":"1878_CR29","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","volume":"33","author":"CE Geyer","year":"2022","unstructured":"Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer. Ann Oncol. 2022;33:1250\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.159.","journal-title":"Ann Oncol"},{"key":"1878_CR30","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Lederer B, Hauke J, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol. 2017;3:1378. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1007.","journal-title":"JAMA Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01878-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:58:33Z","timestamp":1787839113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1878"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01878-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Supplementary file was missing from this article and has now been uploaded.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bogdan-Valentin Popescu has reported travel grants from Stemline Menarini. The remaining authors declare that they have no competing interests related to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was validated and registered with the local ethics committee of the ICANS (registry N\u00b0: IRB-2024-26) and followed the MR-004 methodology for retrospective multicenter studies. Non-opposition letters for inclusion in the analysis were sent to each patient by each individual center.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}